Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.00 Average Target Price from Brokerages

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been assigned an average rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $8.00.

A number of research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday, December 29th. Roth Mkm reissued a “buy” rating and set a $10.00 target price on shares of Gain Therapeutics in a research report on Friday, December 19th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Friday, December 19th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GANX. Marshall Wace LLP grew its holdings in Gain Therapeutics by 849.3% during the fourth quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock valued at $5,353,000 after purchasing an additional 1,487,186 shares during the last quarter. Potomac Capital Management Inc. bought a new position in shares of Gain Therapeutics in the fourth quarter valued at approximately $3,252,000. Jane Street Group LLC lifted its stake in shares of Gain Therapeutics by 234.5% in the fourth quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock worth $780,000 after buying an additional 169,878 shares during the last quarter. LPL Financial LLC bought a new stake in shares of Gain Therapeutics during the 4th quarter worth $343,000. Finally, State Street Corp boosted its holdings in shares of Gain Therapeutics by 72.9% during the 4th quarter. State Street Corp now owns 157,537 shares of the company’s stock worth $507,000 after buying an additional 66,400 shares during the period. 11.97% of the stock is owned by institutional investors.

Gain Therapeutics Price Performance

NASDAQ GANX opened at $1.95 on Wednesday. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $75.00 million, a PE ratio of -3.20 and a beta of -0.03. Gain Therapeutics has a 12-month low of $1.41 and a 12-month high of $4.34. The company has a 50 day moving average price of $2.15 and a two-hundred day moving average price of $2.36.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.